With much interest have we read the important study on the use of glucose-insulin-potassium (GIK) in diabetic patients undergoing coronary artery bypass grafting by Lazar and coworkers. 1 A potential mechanism underlying the beneficial effect of GIK administration includes metabolic modulation of (post)ischemic myocardium. Lowering of the plasma nonesterified fatty acid (FA) concentration by GIK, associated with mitigation of the noxious effect of high levels of circulating FA on the heart, might be one of the mechanisms responsible for the favorable outcome of GIK treatment. This was an obvious reason for Lazar et al to analyze plasma FA levels throughout their study. Considering the recently renewed interest in GIK for the prevention or treatment of postischemic dysfunction, one might expect more articles in the future that report plasma FA levels.
Response
We greatly appreciate the comments from Drs Visser, van Wezel, and colleagues. We were, of course, particularly interested in the effects of GIK on free fatty acids (FFA) as well as glucose metabolism. At each time point, samples were chilled and subsequently separated and frozen. We did not utilize inhibitors of lipoprotein lipase (LPL) and agree that future studies might benefit from use of these agents. We continue to believe that even with this potential improvement, the trends over time and relationships between control and GIK subjects would persist. The first observed trend was the rise in FFA after baseline before cardiopulmonary bypass ("pre CPB" in Figure 3 1 ). We agree that this rise was almost certainly due to the heparin (3 mg/kg)-induced stimulation of LPL. The second trend was the subsequent decrease in both control and GIK subjects at time "0" in the intensive care unit; this observation is consistent with the short-lived effect of heparin on 1 of the 6 time points measured. The third trend was the subsequent relative decrease in FFA in patients receiving GIK compared with controls (time 0 and 6 hours in Figure 3 1 ). This decrease could have been due to either insulininduced inhibition of endogenous lipolysis or cellular transport of FFA. Because the heparin effect seems to have abated, we don't believe that LPL inhibitors would have substantively changed this observation. We believe each of these 3 trends would persist, even if ex vivo lipolysis were minimized by inhibitors. The major benefit of inhibiting LPL would be to determine a threshold level of toxicity of in vivo FFA to myocardium. This may well be a fruitful area of future research. In our study, 1 we have tried to focus on the trends and comparisons without emphasizing the absolute concentrations. In our future studies, we plan to incorporate inhibitors of LPL in our assays as we attempt to correlate changes in FFA with markers of inflammation and oxidative stress to better define the mechanisms for GIK's favorable effects.
